SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MedImmune
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Larry Liebman who started this subject2/5/2004 8:18:30 AM
From: IRWIN JAMES FRANKEL   of 416
 
07:22
MEDI upgraded at JP Morgan (23.35 )

JP Morgan upgrades MedImmune to Overweight from Neutral, saying the mkt is overly focused on the short-term prospects of FluMist and is disregarding the long-term growth opportunities that exist, including the value of its pipeline (particularly Numax) and the strength of its technical assets.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News